GLP-1 receptor agonists
This page files the incretin-related drug names used in the wiki. It is not a comparison of efficacy.
What the opened sources say
Section titled “What the opened sources say”- FDA says some patients and clinicians look to unapproved versions of GLP-1 receptor agonist drugs, including semaglutide and tirzepatide, for weight loss, and that unapproved versions are not reviewed for safety, effectiveness, and quality before marketing.
- FDA says compounded drugs are not FDA-approved. It says a compounded drug might be appropriate when a patient’s medical need cannot be met by an approved drug, or when the approved drug is not commercially available.
- FDA says retatrutide and cagrilintide cannot be used in compounding under federal law, are not components of FDA-approved drugs, and have not been found safe and effective for any condition.
- FDA says it has warned telehealth companies marketing unapproved drugs such as retatrutide, API distributors selling retatrutide and other GLP-1 drugs to compounders, and outsourcing facilities repackaging retatrutide.
- FDA says it has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide, or mazdutide falsely labeled for research purposes or not for human consumption, sometimes with dosing instructions and sold for human use.
- FDA says semaglutide sodium and semaglutide acetate are different active ingredients from the ones in the approved drugs, and that it is not aware of a lawful basis for using those salts in compounding.
- As of 31 May 2026, FDA says it had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. It says causality is not always clear, and that reporting from pharmacies that are not outsourcing facilities is not required, so underreporting is likely.
- FDA describes a green-list import alert, number 66-80, aimed at GLP-1 active pharmaceutical ingredients with potential quality concerns. It says the alert does not apply to API from manufacturers that appear, after an FDA inspection or other evaluation, to comply with manufacturing standards, and that it does not create new limits on legal compounding.
- FDA says it has received adverse-event reports, some requiring hospitalization, that may relate to dosing errors with compounded injectable semaglutide, and reports that may relate to compounded semaglutide or tirzepatide prescribed beyond the approved label. This page does not repeat any dose or measuring method.
Not stated here
Section titled “Not stated here”Brand-name application numbers were not pulled from Drugs@FDA for this draft, so brand lists are omitted except where the FDA page itself uses a name. Mechanisms, trial endpoints, and effect sizes are not restated.
This page does not give doses, titration schedules, injection or implantation technique, preparation steps, or places to purchase a product.
See also
Section titled “See also”Page record
Sources
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (primary, accessed 2026-11-20)
Referenced by
- Cagrilintide
- Continuous glucose monitors
- Import Alert 66-80
- Lyophilized peptides: what this wiki will not instruct
- Mazdutide
- Metabolic health and nutrition
- Peptides
- Research-use labeling in the United States
- Retatrutide
- Semaglutide
- Survodutide
- Tirzepatide
A link from another wiki page is not evidence. Facts should point at the sources above.